The development of an effective vaccine that elicits a strong and durable T cell response
against intracellular pathogens and cancer is a challenge. One strategy to enhance the …

Complement receptors (CR) 3 and 4 belong to the family of beta-2 (CD18) integrins. CR3
and CR4 are often co-expressed in the myeloid subsets of leukocytes, but they are also …

Monoclonal antibody (mAb) drugs that stimulate antitumor immunity are transforming cancer
treatment but require optimization for maximum clinical impact. Here, we show that, unlike …

A high activatory/inhibitory FcγR binding ratio is critical for the activity of mAb such as
rituximab and alemtuzumab that attack cancer cells directly and eliminate them by recruiting …

Allergens are recognized as the proteins that induce immunoglobulin E (IgE) responses in
humans. The proteins come from a range of sources and, not surprisingly, have many …

Dendritic cells (DCs) are best known for their ability to activate naive T cells, and emerging
evidence suggests that distinct DC subsets induce specialized T cell responses. However …

Dendritic cells (DCs) are the most potent professional antigen presenting cells and are
therefore indispensable for the control of immunity. The technique of antibody mediated …

Antibodies are important for vaccine efficacy. Targeting antigens to antigen-presenting cells
(APCs) increases antibody levels. Here, we explore the role of antigen valency in MHC class …

Abstract mAbs specific for surface proteins on APCs can serve as Ag-delivery vehicles that
enhance immunogenicity. The practical use of such constructs is limited by the challenge of …

Current influenza vaccines mostly aim at the induction of specific neutralizing antibodies.
While antibodies are important for protection against a particular virus strain, T cells can …